Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.

Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8.

2.

Histone deacetylase inhibitors in programmed cell death and cancer therapy.

Marks PA, Jiang X.

Cell Cycle. 2005 Apr;4(4):549-51. Review.

PMID:
15738652
3.

Thioredoxin in cancer--role of histone deacetylase inhibitors.

Marks PA.

Semin Cancer Biol. 2006 Dec;16(6):436-43. Review.

4.

Histone deacetylase inhibitors: molecular mechanisms of action.

Xu WS, Parmigiani RB, Marks PA.

Oncogene. 2007 Aug 13;26(37):5541-52. Review.

PMID:
17694093
5.

Histone deacetylase inhibitors: Potential in cancer therapy.

Marks PA, Xu WS.

J Cell Biochem. 2009 Jul 1;107(4):600-8. doi: 10.1002/jcb.22185. Review.

6.

Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.

Jazirehi AR.

Anticancer Drugs. 2010 Oct;21(9):805-13. doi: 10.1097/CAD.0b013e32833dad91. Review.

PMID:
20679890
7.

Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.

Tonissen KF, Di Trapani G.

Mol Nutr Food Res. 2009 Jan;53(1):87-103. doi: 10.1002/mnfr.200700492. Review.

PMID:
18979503
8.
Items per page

Supplemental Content

Support Center